<DOC>
	<DOCNO>NCT03104400</DOCNO>
	<brief_summary>This Phase 3 multicenter study include two period . Period 1 design compare safety , tolerability , efficacy ABT-494 Dose A daily ( QD ) Dose B QD versus placebo versus adalimumab every week ( eow ) participant moderately severely active Psoriatic Arthritis ( PsA ) inadequate response non-biologic DMARDs ( DMARD-IR ) . Period 1 also design compare efficacy ABT-494 Dose A QD Dose B QD versus placebo prevention structural progression . Period 2 evaluates safety , tolerability efficacy ABT-494 Dose A QD Dose B QD participant PsA complete Period 1 .</brief_summary>
	<brief_title>A Study Comparing ABT-494 Placebo Adalimumab Participants With Psoriatic Arthritis Who Have Inadequate Response Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Rheumatic Diseases</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Clinical diagnosis PsA symptom onset least 6 month prior Screening Visit fulfillment Classification Criteria PsA ( CASPAR ) criterion . Participant active disease Baseline define &gt; = 3 tender joint ( base 68 joint count ) &gt; = 3 swollen joint ( base 66 joint count ) Screening Baseline Visits . Presence either Screening : 1 . &gt; = 1 erosion xray determine central image review ; 2. hsCRP &gt; laboratory define upper limit normal ( ULN ) . Diagnosis active plaque psoriasis document history plaque psoriasis . Participant inadequate response ( lack efficacy minimum 12 week duration therapy ) previous current treatment least 1 nonbiologic DMARD maximally tolerate dose ( MTX , SSZ , LEF , apremilast , bucillamine iguratimod ) , participant intolerance contraindication DMARDs define investigator . Participant current treatment concomitant nonbiologic DMARDs study entry must &lt; = 2 nonbiologic DMARDs ( except combination MTX leflunomide ) . The following nonbiologic DMARDs allow : MTX , sulfasalazine , leflunomide , apremilast , HCQ , bucillamine iguratimod , ongoing &gt; = 12 week stable dose &gt; = 4 week prior Baseline Visit . No DMARDs permit study . . Participants need discontinue DMARDs prior Baseline Visit comply inclusion criterion must follow procedure specify least five time mean terminal elimination halflife drug : 1 . &gt; = 8 week LEF elimination procedure follow , adhere elimination procedure ( i.e. , 11 day cholestyramine , 30 day washout activate charcoal per local label ) ; 2 . &gt; = 4 week others . Prior exposure Janus Kinase ( JAK ) inhibitor ( include limit ruxolitinib , tofacitinib , baricitinib , filgotinib ) . Current treatment &gt; 2 nonbiologic DMARDs ; use DMARDs methotrexate , sulfasalazine , leflunomide , apremilast , hydroxychloroquine , bucillamine , iguratimod ; use methotrexate combination leflunomide . History fibromyalgia , arthritis onset prior age 17 year , current diagnosis inflammatory joint disease PsA ( include , limited gout , overlap connective tissue disease , scleroderma , polymyositis , dermatomyositis , systemic lupus erythermatosus ) . Prior history reactive arthritis axial spondyloarthritis include ankylose spondylitis nonradiographic axial spondyloarthritis permit documentation change diagnosis PsA additional diagnosis PsA make . Prior history fibromyalgia permit documentation change diagnosis PsA documentation diagnosis fibromyalgia make incorrectly .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Anti-inflammatory</keyword>
	<keyword>Musculoskeletal disease</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Anti-Rheumatic</keyword>
	<keyword>Joint disease</keyword>
</DOC>